Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
Napoli C, Omboni S, Borghi C; ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group. Napoli C, et al. J Hypertens. 2016 Nov;34(11):2287-97. doi: 10.1097/HJH.0000000000001079. J Hypertens. 2016. PMID: 27653164 Clinical Trial.
Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C. Omboni S, et al. Among authors: napoli c. Adv Ther. 2017 Apr;34(4):784-798. doi: 10.1007/s12325-017-0497-8. Epub 2017 Mar 4. Adv Ther. 2017. PMID: 28260186 Free PMC article. Review.
Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C. Omboni S, et al. Among authors: napoli c. Adv Ther. 2017 Jun;34(6):1498-1499. doi: 10.1007/s12325-017-0537-4. Adv Ther. 2017. PMID: 28452039 Free PMC article. No abstract available.
Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, Mansueto G, De Rosa G, Bonaduce D, Condorelli M, Napoli C. de Nigris F, et al. Among authors: napoli c. Int J Cardiol. 2001 Dec;81(2-3):107-15; discusssion 115-6. doi: 10.1016/s0167-5273(01)00542-3. Int J Cardiol. 2001. PMID: 11744122
Soft drinks and sweeteners intake: Possible contribution to the development of metabolic syndrome and cardiovascular diseases. Beneficial or detrimental action of alternative sweeteners?
Schiano C, Grimaldi V, Scognamiglio M, Costa D, Soricelli A, Nicoletti GF, Napoli C. Schiano C, et al. Among authors: napoli c. Food Res Int. 2021 Apr;142:110220. doi: 10.1016/j.foodres.2021.110220. Epub 2021 Feb 18. Food Res Int. 2021. PMID: 33773688 Free article. Review.
Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.
Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro S, Libardi S, Sommese L, Fiorito C, Mancini FP, Cacciatore F, Liguori A. Napoli C, et al. Am Heart J. 2008 Dec;156(6):1154.e1-8. doi: 10.1016/j.ahj.2008.09.006. Am Heart J. 2008. PMID: 19033012 Clinical Trial.
796 results